PubMed Health⌕ Search

Biomedical subjects

C Doutremepuich

Publications and source records attributed to C Doutremepuich.

At least 91 records · Page 5Linked to original sources
PubMed1984

Aortic valve homografts in the surgical treatment of complex cardiac malformations.

From April of 1968 to March of 1983, the surgical treatment of complex congenital cardiac malformations requiring an extracardiac conduit for their correction was performed with aortic valve homografts or aortic valved homograft conduits sterilized and preserved in our hospital. Our experience concerns 93 patients in whom a total of 103 aortic valve homografts were implanted. Ages of the patients ranged from 7 months to 36 years (mean 11.6 years). The aortic valve homografts were used from the right atrium to the pulmonary arteries or right ventricle (right atrium-dependent conduit), from the venous ventricle to the pulmonary arteries (ventricle-dependent conduit), or in the pulmonary orifice and in the superior and/or inferior venae cavae. There were 25 early and nine late deaths (36.5%), none of them related to the aortic valve homograft. The clinical follow-up of the 59 survivors (1 month to 15 years, mean 4.3 years) evidenced neither dysfunction of the aortic valve homograft nor thromboembolism or hemolysis; 93% of the patients are in New York Heart Association Class I or II. Control cardiac catheterization in 53 patients evidenced a pressure gradient in only 14 ventricle-dependent conduits. In seven patients with serial control catheterizations after 5 to 10 years, the pressure gradient had not increased.

Adolescent↗
PubMed1983

Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis.

In human volunteers unfractionated heparin and a low molecular weight fraction of heparin (LMWH) caused an increase in plasma plasminogen activator (PA) which peaked at 3 hours after subcutaneous injection. Using a perfused isolated rabbit ear model the enhancement of PA activity was confirmed and was related to the anti-Xa activity of both products infused. Using a modified rabbit Wessler model for thrombus formation it was found that, when using doses of heparin and LMWH sufficient to give a 100% antithrombotic effect, antifibrinolytic drugs (eg. epsilon-ACA and aprotinin), negated this protective effect. It is concluded that the effect of heparin and LMWH on haemostasis is mediated in part through the enhancement which these drugs have on fibrinolysis, the latter being arguably a major defence against fibrin formation during thrombosis.

Animals↗
PubMed1983

Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction.

An unfractionated mucosal heparin preparation and a low molecular weight heparin fraction were randomly administered to rats subcutaneously. This injection was made on rats with experimentally induced venous thrombosis. At high doses (6.66 mg/kg) of both drugs, thrombus mean weight was reduced in comparison with a control group. At lower doses (2.22 mg/kg) these two drugs inhibited the growth of the thrombus. This inhibition was obtained with a lower dose (0.66 mg/kg) of the low molecular weight heparin fraction than of heparin. The low molecular weight heparin fraction (molecular weight 5,000 daltons) has a high anti-Xa activity (200 units) and a low activity determined by the USP assay (50 units).

Animals↗
PubMed1977

[Variations in hemostasis in the infant under deep hypothermia].

Effects on hemostasis of deep hypothermia on infant has been studied on 29 infants operated upon for a cardiopathy under deep hypothermia. Results of this study show a diminution of the coagulation factors rate, an augmentation of the fibrinolytic activity and an unforeseable variability of the residual heparin leading in all cases to a complement of the heparin neutralization by Protamine.

Cardiac Surgical Procedures↗
PubMedDate not supplied

Prevention of laser arterial thrombus formation with unfractionated heparin.

A method to induce microthrombi in small mesenteric arteries (30-40 microns) has been developed to study platelet reactions and to investigate antithrombotic drugs. This model was used to evaluate the effect of Ca-heparin. Mesenteric lesions are induced in the vascular system of Wistar rats with an argon laser. The laser induced the formation of vessel wall lesion with damage of endothelial cells. Thrombi formed within seconds after the laser lesion and grew rapidly. Embolization began within a minute following the laser flash. Thrombus formation and embolization were repetitive phenomena. The administration of Ca-heparin at different dosages (0.5, 1.0 and 2.0 mg/kg) increases the number of laser injuries required to induce thrombus formation, and dose-dependently decreases the number of emboli and the duration of embolization. The highest dose injected (2.0 mg/kg) induced the strongest reduction in the number of emboli and duration of embolization.

Animals↗
PubMedDate not supplied

[Artificial blood: the future of blood transfusion? I. Hemoglobin solutions].

To palliate certain drawbacks in blood transfusion, some preparations are studied as oxygen-transporting erythrocytic substitutes; these are preparations of a biological origin such as hemoglobin solutions, or synthetic preparations such as fluorocarbon emulsions. Part 1 studies solutions of purified, pyridoxylated and/or polymerized hemoglobin of human or animal origin.

Blood Substitutes↗